DK2376536T3 - Midler mod pemphigus, som indeholder antistoffer mod fas-liganden - Google Patents

Midler mod pemphigus, som indeholder antistoffer mod fas-liganden Download PDF

Info

Publication number
DK2376536T3
DK2376536T3 DK09801201.6T DK09801201T DK2376536T3 DK 2376536 T3 DK2376536 T3 DK 2376536T3 DK 09801201 T DK09801201 T DK 09801201T DK 2376536 T3 DK2376536 T3 DK 2376536T3
Authority
DK
Denmark
Prior art keywords
fasl
tyr
ser
antibody
pemphigus
Prior art date
Application number
DK09801201.6T
Other languages
English (en)
Inventor
Carlo Pincelli
Alessandra Marconi
Original Assignee
Pincell Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2008/010597 external-priority patent/WO2009074339A1/en
Application filed by Pincell Srl filed Critical Pincell Srl
Application granted granted Critical
Publication of DK2376536T3 publication Critical patent/DK2376536T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (6)

1. Forbindelse valgt blandt: (i) et monoklonalt humant antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæ-de-region, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR, complementary determining regions) i den tunge kæde er: am m: Arp His 8# Tf*r I« SO Hø: 13}eller (to) GØR H1 r Ser His Oly Is $«r ($£Q tO RØ; 14), QtM H2: Trp 1# Asm Als Tyr Asn Oly Am Ihr Am Tyr Als Gin tys Vsl Øls Gfy (SEØ 10 HD; 1$) eller 15¾) 000 Hit Ifp is ΑΙ» Tyr Ser Oly Asn TPr Asn Tyr Ais Gtn tys teu m% Gly CSEQ 10 Hø: 16)* |5s| ØØR H3: Glu TPr Rist Ve! Arp øfy Vs! Prs Lmi A$p Tyr (SEølOHø: 17) eller cm H3: OlM TAr Met Vs! Arp Ofy Vs! Prs Cys Asp Tyr (SEQ 10 NO: 1ST og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er f%) CDR il; Arp Als Os? øls Ssr Vat Ser Ser Ssr Tyr is« Als fSiø !D HD: 1% 11¾) CDR it: Gly Als Ser Sar Arg Als Tbr |Sm ID Hø; 28), C«s| COR13: Øn øls Tyr Oly Sar Ost Rra Trp TPr (Siø ID HØ: 21) og (ii) et antistof eller et antigenbindende fragment deraf, som genkender den samme epitop på humant FasL som et antistof med en variabel letkæde-region, der omfatter aminosyresekvensen yYGÅSS^TeiPORfegSGSGTDFTtTlSRtEPEDFmArYCSa^i og den variable tungkæde-region, der omfatter aminosyresekvensen cmtmBSÅE^KRPaåSWCWOlCASGYFIEliSEWVROåPmeiRW yBVV»MåYRtSNTMYAOBYQORWM?TORSTSTAYIIi:LR8iPI:^>PAA¥ eller OVaiYCBG^KICf^SVKYSOimSOWf^fflSWVRQ^PGaGLeW til anvendelse til forebyggelse og/eller behandling af pemphigus.
2. Forbindelse til anvendelsen ifølge krav 1, hvor forbindelsen er: (i) et monoklonalt humant antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæ-de-region, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den tunge kæde er: fa,f CDR H1> Ail His Oly S§# Thr (SEG ID MG:: 13|* ø# 038 H£: Τφ 8» fim .Als Tyr fim Giy fim Th? fim Tyr Ab Ofrs lpVs! ofe GI? (SEQ 10 NO: IS), fca) CPR m Thr tm Val Af$ Off Var Pm Im Asp Tyr fSEG ID NO: 17}.. og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er f%) CDR il: Ast) Ab S«? CVn Sar Val Sar Sar Sar Tyr Laa Als pSOIDNOifiT lis) ØOR tt: GI? Ala Sar Sar Arp Als Tfcr fSEQ 10 NO: W% COR U: Ola Ola Tyr Oly Sar Sar Rra Trp Thr C'SEO ID NO: 21) til anvendelse til forebyggelse og/eller behandling af pemphigus.
3. Forbindelse til anvendelsen ifølge krav 1, hvor forbindelsen er: (i) et monoklonalt humant antistof eller et antigenbindende fragment deraf, som er specifikt for humant Fas-ligandprotein (FasL), hvor det monoklonale antistof omfatter mindst én variabel tungkæde-region og mindst én variabel letkæ-de-region, hvor aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den tunge kæde er: (éé Om Hl: Ser His U (SEQ !S> NC& py €01¾ H2; Trp 1¾ A$r* Als Tyr §*f Ofy Mm Ihr tei Tyt te m lp Ui* Qiy iSSO ID NO; li), {CssJ OPR H3: GO Tøf Vii Arg Gly V*l Fro Cys Asp Tyr (SIO ID NO; IS), og aminosyresekvenserne i de komplementaritetsbestemmende regioner (CDR) i den lette kæde er CDR LI: Arg Afe Ser Gift Ser Val Ser Ser Ser Tyr Im Mm mm ID NO; 10), fi&> CDR 12: Dly Als Ser Ser Arg Ala Thf |SEQ ID NO; 2D), |rs) DDR U; Oie Ole Tyt Oly Ser Ser Pro Trp Tøf (SIG 10 NO; 211 til anvendelse til forebyggelse og/eller behandling af pemphigus.
4. Forbindelse til anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor antistoffet eller et antigenbindende fragment deraf er valgt blandt et delvist eller helt humaniseret antistof, et delvist eller helt humaniseret enkeltkædet antistof eller et fragment deraf.
5. Forbindelse til anvendelsen ifølge et hvilket som helst af de foregående krav, hvor forbindelsen anvendes i en kombinationsbehandling sammen med mindst én yderligere behandling, som er effektiv mod pemphigus.
6. Forbindelse til anvendelsen ifølge krav 5, hvor forbindelsen anvendes i kombination med mindst ét yderligere immunosuppressivt lægemiddel, navnlig med mindst ét yderligere steroid.
DK09801201.6T 2008-12-12 2009-12-14 Midler mod pemphigus, som indeholder antistoffer mod fas-liganden DK2376536T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2008/010597 WO2009074339A1 (en) 2007-12-12 2008-12-12 Remedies for pemphigus containing anti fas ligand antobodies
PCT/EP2009/067129 WO2010066914A2 (en) 2008-12-12 2009-12-14 Remedies for pemphigus containing anti fas ligand antibodies

Publications (1)

Publication Number Publication Date
DK2376536T3 true DK2376536T3 (da) 2015-06-08

Family

ID=42060995

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09801201.6T DK2376536T3 (da) 2008-12-12 2009-12-14 Midler mod pemphigus, som indeholder antistoffer mod fas-liganden

Country Status (20)

Country Link
US (1) US9255150B2 (da)
EP (1) EP2376536B1 (da)
JP (1) JP5773882B2 (da)
KR (1) KR101769858B1 (da)
CN (1) CN102405234A (da)
AU (1) AU2009326978B2 (da)
BR (1) BRPI0922201A2 (da)
CA (1) CA2746334C (da)
DK (1) DK2376536T3 (da)
ES (1) ES2534799T3 (da)
HK (1) HK1161884A1 (da)
IL (1) IL213213A (da)
MX (1) MX2011006203A (da)
NZ (1) NZ593312A (da)
PL (1) PL2376536T3 (da)
PT (1) PT2376536E (da)
RU (1) RU2556818C2 (da)
SI (1) SI2376536T1 (da)
WO (1) WO2010066914A2 (da)
ZA (1) ZA201104130B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015165973A1 (en) * 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
CA2999116A1 (en) 2015-09-23 2017-03-30 Apogenix Ag Anti-cd95l antibody
RU2613718C1 (ru) * 2015-11-24 2017-03-21 Федеральное государственное бюджетное учреждение "Государственный научный центр дерматовенерологии и косметологии" Минздрава России (ФГБУ ГНЦДК Минздрава России) Способ моделирования пузырчатки у мышей методом введения иммуноглобулинов класса g
CN116888257A (zh) * 2022-01-21 2023-10-13 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029350A1 (fr) 1995-03-20 1996-09-26 Sumitomo Electric Industries, Ltd. ANTICORPS MONOCLONAL REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas ET SON PROCEDE DE PRODUCTION
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
CN1196733A (zh) 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
EP1642908A2 (en) 1996-09-02 2006-04-05 Okumura, Ko Apoptosis-induced site from fas ligand
JP2005520523A (ja) * 2002-03-21 2005-07-14 イーライ・リリー・アンド・カンパニー アンタゴニスト的抗hFasリガントヒト抗体およびそのフラグメント
DK2231708T3 (da) 2007-12-12 2015-07-13 Pincell Srl Midler mod pemphigus, som indeholder antistoffer mod fas-liganden
FR2933264B1 (fr) 2008-06-25 2012-10-26 Actimagine Procede d'authentification d'un utilisateur d'un service sur terminal mobile.

Also Published As

Publication number Publication date
AU2009326978A1 (en) 2011-07-07
SI2376536T1 (sl) 2015-04-30
MX2011006203A (es) 2011-07-20
RU2556818C2 (ru) 2015-07-20
RU2011128702A (ru) 2013-01-20
BRPI0922201A2 (pt) 2015-12-29
WO2010066914A2 (en) 2010-06-17
NZ593312A (en) 2013-02-22
HK1161884A1 (en) 2012-08-10
CN102405234A (zh) 2012-04-04
CA2746334C (en) 2018-06-12
JP2012511550A (ja) 2012-05-24
US20110243946A1 (en) 2011-10-06
PL2376536T3 (pl) 2015-10-30
EP2376536B1 (en) 2015-02-25
AU2009326978B2 (en) 2013-09-12
IL213213A0 (en) 2011-07-31
ES2534799T3 (es) 2015-04-29
US9255150B2 (en) 2016-02-09
ZA201104130B (en) 2012-02-29
EP2376536A2 (en) 2011-10-19
KR20110094327A (ko) 2011-08-23
PT2376536E (pt) 2015-05-11
CA2746334A1 (en) 2010-06-17
WO2010066914A3 (en) 2010-09-02
KR101769858B1 (ko) 2017-08-21
IL213213A (en) 2015-10-29
JP5773882B2 (ja) 2015-09-02

Similar Documents

Publication Publication Date Title
DK2231708T3 (da) Midler mod pemphigus, som indeholder antistoffer mod fas-liganden
US9114131B2 (en) Antibody targeting osteoclast-related protein Siglec-15
EP3170841A1 (en) NOVEL ANTI-HUMAN Tie2 ANTIBODY
AU2011349124B2 (en) Anti-P-selectin antibodies and methods of their use and identification
DK2376536T3 (da) Midler mod pemphigus, som indeholder antistoffer mod fas-liganden
EA041723B1 (ru) Анти-c5 антитела и их применение